Form 4: Mirum Pharmaceuticals Director Saira Ramasastry Acquires Shares and New Equity Awards

Mirum Pharmaceuticals Director Saira Ramasastry reported the acquisition of 5,703 shares of common stock through RSU vesting, alongside new grants of 6,268 stock options and 3,977 restricted stock units.

Summary

• Saira Ramasastry, a Director at Mirum Pharmaceuticals, Inc. (MIRM), reported transactions on May 29, 2025.
• The director acquired 5,703 shares of common stock directly, resulting from the vesting of 5,703 Restricted Stock Units (RSUs).
• Additionally, the director was granted 6,268 stock options with an exercise price of $44, which will vest on the first anniversary of the grant date or fully by the Issuer's 2026 annual stockholder meeting, and expire on May 28, 2035.
• Another 3,977 Restricted Stock Units (RSUs) were acquired, which will vest on the first anniversary of the grant date or fully by the Issuer's 2026 annual stockholder meeting.

Sentiment

Score: 8

Explanation: The acquisition of common stock and the grant of new equity awards to a director are generally positive signals, indicating continued alignment of interests and confidence in the company's future prospects.

Positives

• Director Saira Ramasastry acquired 5,703 shares of common stock, increasing direct ownership and aligning interests with shareholders.
• The director received new equity awards, including 6,268 stock options and 3,977 Restricted Stock Units, indicating continued commitment and incentive alignment with the company's long-term performance.
• The vesting of existing RSUs into common stock demonstrates the realization of previously granted equity compensation.

Future Outlook

The document details future vesting schedules for equity awards, with 5,703 Restricted Stock Units vesting by the 2025 annual stockholder meeting and 6,268 stock options and 3,977 Restricted Stock Units vesting by the 2026 annual stockholder meeting, aligning future compensation with company performance.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in the biotechnology and pharmaceutical industry, where stock options and restricted stock units are commonly used to align executive and director interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The transactions indicate continued alignment of a director's interests with shareholders through equity ownership and future performance-based incentives.
• Employees: While not directly impacting employees, the equity compensation structure for directors often mirrors broader company-wide incentive programs.

Next Steps

• The vesting of 5,703 Restricted Stock Units is expected to be fully completed by the Issuer's 2025 annual stockholder meeting.
• The vesting of 6,268 stock options and 3,977 Restricted Stock Units is expected to be fully completed by the Issuer's 2026 annual stockholder meeting.

Key Dates

Recommendation

Keywords

Mirum Pharmaceuticals, MIRM, Saira Ramasastry, SEC Form 4, Insider Trading, Director Stock Acquisition, Restricted Stock Units, Stock Options, Equity Compensation, Vesting